Hanx Biopharmaceuticals’ HX009 Receives NMPA Clearance for TNBC Study
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clearance from the National Medical...
PD-1/L1
Sunshine Guojian and Shenyang 3SBio License 612 and 708 Programs for Anti-Tumor Development
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd and Shenyang 3SBio Co., Ltd, both subsidiaries of...
Zelgen Biopharmaceuticals’ ZG005 Bispecific Antibody Receives NMPA Approval for Biliary Tract Cancer Trials
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial...
Innovent Biologics’ IBI363 Receives FDA Fast-Track Designation for sqNSCLC
China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another fast-track designation from...
Bristol Myers Squibb’s Opdualag Fails to Meet Primary Endpoint in Melanoma Study
US pharmaceutical major Bristol-Myers Squibb (BMS, NYSE: BMY) provided an update on the RELATIVITY-098 study...
Henlius Biotech Doses First Patient in HLX43 Phase II Study for Esophageal Cancer
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in a Phase II...
Changchun GeneScience’s GenSci120 Receives NMPA Approval for Rheumatoid Arthritis Trials
China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another clinical trial approval...
NMPA Approves Sinocelltech’s Finotonlimab for Head and Neck Cancer
The National Medical Products Administration (NMPA) of China has approved Sinocelltech Group Ltd’s (SHA: 688520)...
Eli Lilly’s Q4 Sales Soar 45% to $13.53B on Strength of GLP-1 Drugs
Eli Lilly & Co. (NYSE: LLY) reported a robust finish to 2024, with Q4 revenues...
Junshi Biosciences Receives NMPA Approval for JS213 Clinical Trials
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...
Akeso Biopharma Receives Development Payment for PD-L1 Monoclonal Antibody
China-based Akeso Biopharma (HKG: 9926) has announced receiving a drug collaboration development payment from compatriot...
GSK’s Jemperli Approved for First-Line Endometrial Cancer Treatment in EU
UK-based GSK plc (NYSE: GSK, LON: GSK) has announced receiving approval from the European Commission...
Kelun-Biotech’s Tagitanlimab Receives NMPA Clearance for Nasopharyngeal Carcinoma
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced receiving another clearance from the...
Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced a licensing agreement...
Junshi Biosciences’ Toripalimab Gains TGA Approval for Nasopharyngeal Carcinoma
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving marketing approval...
Merck’s Keytruda Gains NMPA Approval for HNSCC Indication in China
US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) has announced that it has received...
MediLink Therapeutics and AstraZeneca Collaborate on YL201 and Imfinzi Combo for Solid Tumors
Suzhou-based biotech company MediLink Therapeutics (Suzhou) Co., Ltd has announced a clinical cooperation agreement with...
Henlius Biotech Gains NMPA Clearance for HLX43 ADC Study
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that it has received clearance from...
Pfizer’s Sasanlimab Shows Positive Results in Phase III CREST Study
US-based Pfizer Inc. (NYSE: PFE) has reported positive topline results from its pivotal Phase III...
Astellas’ Padcev and Keytruda Combo Cleared by NMPA for Urothelial Cancer
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced marketing clearance by China’s National Medical Products...